FoundationOne CDx is now FDA-approved as the first companion diagnostic for tovorafenib, enabling targeted treatment for ...

AstraZeneca AZN announced that the FDA has approved its antibody-drug conjugate (ADC), datopotamab deruxtecan (or Dato-DXd), ...

J&J JNJ announced fourth-quarter and full-year 2024 results, starting the earnings season for the drug and biotech sector.

Eli Lilly and its subsidiary, Avid Radiopharmaceuticals, have announced that the European Commission has approved Amyvid (Florbetapir (18F)) solution for injection as a diagnostic radiopharmaceutical.

26, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that a phase I/II clinical trial (Study ID: JSKN033-102) of JSKN033, a high-concentration subcutaneous co-formulation ...

With the global rise in cancer incidence, PH Pharma projects that the ADC market will grow to $22 billion by 2030. The number of FDA-approved ADC drugs is also on the rise. Since Pfizer’s ...

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...

One is against nectin-four, a target which already has an ADC at market courtesy of Pfizer’s Padcev (enfortumab vedotin), though Grabulovski says Araris’ candidate has three different payloads as a ...

Roche has licensed rights to a DLL3-directed antibody-drug conjugate (ADC) from China's Innovent Biologics, hoping to bring a competitor to Amgen's recently approved Imdelltra to market.